Mark A Meltz Kinnate Biopharma Inc. (KNTE) insider trading activity

Mark A Meltz is COO GENERAL COUNSEL SECRETARY of Kinnate Biopharma Inc.. Currently has a direct ownership of 0 shares of KNTE, which is worth approximately $0. The most recent transaction as insider was on Apr 03, 2024, when has been sold 27,578 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Mark A Meltz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 03 2024	SELL Sale (or disposition) back to the issuer	-	27,578 Reduced 100.0%	0 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$1,445 $2.59 p/Share	558 Reduced 1.98%	27,578 Common Stock
Dec 01 2023	SELL Payment of exercise price or tax liability	$1,217 $2.25 p/Share	541 Reduced 1.89%	28,136 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$1,271 $2.35 p/Share	541 Reduced 1.85%	28,677 Common Stock
Jun 01 2023	SELL Payment of exercise price or tax liability	$2,326 $4.3 p/Share	541 Reduced 1.82%	29,218 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$3,323 $5.21 p/Share	638 Reduced 2.28%	27,286 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$4,192 $7.75 p/Share	541 Reduced 1.9%	27,924 Common Stock

Sep 01 2022	BUY Grant, award, or other acquisition	-	25,000 Added 46.76%	28,465 Common Stock

MAM

Mark A Meltz

COO GENERAL COUNSEL SECRETARY

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNTE shares.

Notify only if

Value

Insider Trading

Get notified when an Kinnate Biopharma Inc. insider buys or sells KNTE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kinnate Biopharma Inc.

Track Activities on KNTE

Account